全球首个且唯一双亚型全身型重症肌无力药物国内获批

Core Insights - The approval of Rozelizumab injection (brand name Youdige) marks a significant advancement in the treatment of adult generalized myasthenia gravis (gMG) patients who are positive for acetylcholine receptor (AChR) or muscle-specific kinase (MuSK) antibodies, filling a gap in targeted therapy for MuSK-positive patients in China [1][2] - Myasthenia gravis is a rare autoimmune neuromuscular transmission disorder that can lead to severe muscle weakness and fatigue, with a notable risk of respiratory failure in critical cases [1] - The annual incidence of myasthenia gravis in China is reported to be 0.68 per 100,000, with AChR-positive and MuSK-positive subtypes accounting for approximately 85% and 8% of cases, respectively [1] Group 1 - Rozelizumab injection is the first and only neonatal Fc receptor (FcRn) antagonist that targets both AChR-positive and MuSK-positive gMG [1] - The approval of this drug provides a more targeted treatment option for myasthenia gravis patients, which is expected to significantly improve their quality of life and facilitate their return to normal activities [2] Group 2 - Diagnosis of myasthenia gravis is relatively clear compared to other rare diseases, and with active and standardized treatment, most patients can effectively control their condition [2] - However, controlling the disease does not equate to a full restoration of quality of life, highlighting the importance of new treatment options like Rozelizumab [2]